ChinaBulls

Wuhan Neurophth Biotechnology Limited Company纽福斯

Biotech/Healthcare

The company has successfully designed a gene therapy candidate for Leber hereditary optic neuropathy (LHON). To date, it has completed clinical trials involving 152 LHON patients, including seven patients in Argentina.

Source: ChinaBulls — chinabulls.com

Last updated 2023-08-01

Funding Rounds

  • Series C Extension
    RaisedFunding amount requires an account.

    Create Account to Unlock Full Data for Free

    SIGN UP

Wuhan Neurophth Biotechnology Limited Company Fundraising Info

Company fundraising information requires an account.

Wuhan Neurophth Biotechnology Limited Company Investors and Backers

Unlock Full Data for Free

Get access to market data, insights, backers, analytics and funding rounds.

SIGN UP